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Reduced CXCL4/PF4 expression as a driver of
increased human hematopoietic stem and
progenitor cell proliferation in polycythemia vera
Fabienne Meier-Abt 1,2, Witold E. Wolski3,4, Ge Tan 3, Sandra Kummer1, Sabine Amon2, Markus G. Manz1,
Ruedi Aebersold2,5 and Alexandre P. A. Theocharides1
Dear Editor,
Polycythemia vera (PV) is a myeloproliferative neo-
plasm (MPN) marked by hyperproliferation of all mye-
loid cell lineages and characterized by activated JAK-
STAT signaling due to an activating mutation in JAK21.
Disease-driving pathogenic changes in MPNs are
thought to arise in hematopoietic stem cells (HSCs) that
give rise to the diseased clonal progeny2,3. We recently
developed a new data-independent acquisition (DIA)
mass spectrometry (MS) technology for rare human
hematopoietic stem and progenitor cell (HSPC) sub-
populations4. This DIA-MS proteomic analysis was
applied to human hematopoietic stem/multipotent
progenitor cells (HSC/MPPs) and common myeloid/
megakaryocyte-erythrocyte progenitors (CMP/MEPs)
isolated from 123 blood samples of 18 PV patients and
21 controls (Supplementary Table 1). The proteomic
dataset was complemented with RNA-sequencing data
of the same patient and control samples.
Comparing the proteomic and transcriptomic datasets
in the corresponding patient and control samples
demonstrated mainly positive correlations: 70% of genes
had positive Spearman’s correlation coefficients for
protein and RNA expression. In line with our previous
observations in HSC/MPPs of healthy stem cell donors4,
30% of genes with altered expression in PV patients
and their controls demonstrated negative correlation
coefficients for protein and RNA expression, indicating
additional information gained by proteomic compared
to transcriptomic data.
Downregulation of megakaryocyte differentiation
and upregulation of cell proliferation in PV HSPCs
and its reversal upon treatment with hydroxyurea
(HU)
To further examine the added information provided
by protein compared to RNA expression data, we per-
formed enrichment analyses for gene ontologies in
HSPC subpopulations of PV patients on protein and
RNA levels. Megakaryocyte differentiation and regula-
tion was significantly downregulated in untreated PV
patients at the protein level, but not at the RNA level in
all HSPCs analyzed (Fig. 1A with individual gene
ontology protein members shown in Fig. 1B). Similarly,
RNAs and proteins implicated in DNA replication and
G1/S transition of the mitotic cell cycle were dis-
cordantly regulated in HSC/MPPs of untreated PV
patients (Fig. 1A). In contrast to the discordant protein
and RNA expression in these gene sets, we observed
concordant expression on the protein and RNA level for
erythrocyte differentiation, regulation, development
and maturation, receptor signaling via JAK-STAT,
interferon-gamma signaling, cholesterol biosynthetic
process, and TGFβ and MAPK signaling and regulation
in HSPCs of untreated PV patients compared to controls
(Fig. 1A).
Cytoreductive therapy with hydroxyurea reverted
downregulation of megakaryocyte differentiation and
regulation on protein level (Fig. 1A, B). It also reversed
upregulation of cell proliferation (DNA replication, G1/S
transition of the mitotic cell cycle, DNA repair) on RNA
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level and downregulation of TGFβ signaling on protein
and RNA level (Fig. 1A). Erythrocyte differentiation and
regulation were reversed by hydroxyurea on the protein
but not RNA level, whereas interferon-gamma signaling
was not affected by the treatment of patients with
hydroxyurea (Fig. 1A).
Fig. 1 (See legend on next page.)
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Reduced CXCL4/PF4 expression in HSC/MPPs of untreated
PV patients
To better characterize the molecular phenotype
underlying PV stem and progenitor cell biology, we next
focused on individual differentially regulated proteins in
HSC/MPPs of untreated PV patients compared to con-
trols. Consistent with the downregulation of mega-
karyocyte differentiation and regulation observed in
the gene ontology enrichment analysis (Fig. 1A, B), we
observed significant downregulation of the mega-
karyocytic lineage protein CXCL4/PF4 (platelet factor 4)
(Fig. 1C, D and Supplementary Fig. 1). Intracellular flow
cytometry confirmed the downregulation of CXCL4/PF4
in HSC/MPPs of untreated chronic phase PV patients
in comparison to age- and gender-matched controls
(Fig. 1E). Treatment with hydroxyurea abrogated the
downregulation of CXCL4/PF4 protein expression in PV
HSC/MPPs (Fig. 1D).
Since all PV patients analyzed in this study carried
the JAK2V617F mutation, we tested for a potential
direct relationship between the JAK2V617F allele
burden and CXCL4/PF4 protein expression. No sig-
nificant correlation was observed (Supplementary Fig.
2), suggesting that reduced CXCL4/PF4 expression in
PV is a JAK2V617F allele burden-independent disease
manifestation.
CXCL4/PF4 did not show equally significant expres-
sion changes on the RNA level as on the protein level.
Exploring protein-RNA-correlations in more detail, we
observed that protein and RNA levels became dis-
cordant upon disease progression (Fig. 1F). Upregulated
RNA and downregulated protein levels for CXCL4/PF4
were observed in HSC/MPPs of post-PV myelofibrosis
(MF) patients but not in post-PV acute myeloid leuke-
mia (AML) stem cells. In controls and non-progressed
PV patients, protein and RNA levels of CXCL4/PF4 were
better aligned even if not systematically coordinated
(Fig. 1F).
Decreased ELF1 and USF2 activity explains reduced CXCL4/
PF4 expression, which is linked to downregulated TGFβ
signaling and loss of stem cell quiescence
We next assessed the activities of transcription factors
(TFs), which bind the CXCL4/PF4 promoter and may
regulate CXCL4/PF4 expression in PV HSC/MPPs
(Fig. 2A)5–8. We found a significantly decreased activity
for ELF1 and to a lesser extent also for USF2 in HSC/
MPPs of untreated PV compared to controls and HU-
treated PV (Fig. 2A), suggesting a potential link between
diminished ELF1 and USF2 activity and a reduction of
CXCL4/PF4 expression in HSC/MPPs of untreated PV
patients5,8. Upon progression to post-PV MF, the activ-
ities of the TFs USF2 and also NKX2-2 increased,
potentially explaining upregulated RNA levels of CXCL4/
PF4 in these patients (Supplementary Fig. 3)5.
Reduced CXCL4/PF4 expression in HSC/MPPs of PV
patients was associated with significant upregulation of
genes downregulated in stem cell quiescence both on
RNA (Fig. 2B, D) and protein (Supplementary Fig. 4A and
4C) level9. This pattern was reversed by treatment of
patients with cytoreductive hydroxyurea (Fig. 2C, D and
Supplementary Fig. 4B, C). Mechanistically, CXCL4/PF4
upregulates TGFβ10, which promotes stem cell quies-
cence11. We observed downregulation of TGFβ signaling
in untreated PV patients that also exhibited down-
regulated CXCL4/PF4 levels (Fig. 1A). These data suggest
that reduced CXCL4/PF4 expression in PV HSC/MPPs
leads to the cessation of stem cell quiescence via down-
regulation of TGFβ signaling.
CXCL4/PF4 inhibits colony formation of HSC/MPPs isolated
from untreated chronic phase PV patients
To assess the functional relevance of CXCL4/PF4
downregulation and to examine its causal link to HSC/
MPP proliferation and differentiation in PV, we cultured
HSC/MPPs of untreated chronic phase PV patients in the
presence or absence of CXCL4/PF4 using two independent
(see figure on previous page)
Fig. 1 Comparative unbiased proteomic analysis identifies downregulation of CXCL4/PF4 in HSC/MPPs of PV patients. A Gene set
enrichment analysis (GSEA) comparing untreated PV patients against controls (PV.UT.HSC/MPP versus Control.HSC/MPP; PV.UT.CMP/MEP versus
Control.CMP/MEP) and assessing for the effect of treatment with hydroxyurea (PV.HU.HSC/MPP versus PV.UT.HSC/MPP; PV.HU.CMP/MEP versus
PV.UT.CMP/MEP). Shown are normalized enrichment scores (NES) for individual gene sets. Significantly upregulated gene sets are marked in red
color, significantly downregulated gene sets are marked in blue color. Only RNAs and proteins expressed in at least half of the replicates in both
comparison groups were considered. UT untreated, HU patient under treatment with hydroxyurea. B Heatmap of proteins enriched in different
patient and control groups for megakaryocyte differentiation and regulation. C Volcano plot of protein intensity fold changes and p-values
comparing HSC/MPPs of untreated PV patients (PV.UT.HSC/MPP) against controls (Control.HSC/MPP). D Normalized protein intensities for CXCL4/
PF4 in the subgroups of controls, chronic PV patients without cytoreductive therapy (PVchron.UT), chronic PV patients with hydroxyurea therapy
(PVchron.HU), and progressed PV patients (PVprog). Error bars represent standard deviations. *adj. P < 0.05; **adj. P < 0.01; ***adj. P < 0.001
Peptide profiles for CXCL4/PF4 are provided in Supplementary Fig. 1. E Graphical summary of intracellular FACS staining experiments for CXCL4/
PF4 in six untreated chronic PV patients and age- and gender-matched controls. Error bars represent standard deviations. F Normalized CXCL4/
PF4 expression values for protein and RNA in individual patient and control samples. Discrepant high RNA and low protein levels were seen in
progressed PV patients with fibrosis (post-PV MF) but not in post-PV AML.
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colony formation assays. Supplementation with CXCL4/
PF4 inhibited colony formation of singly sorted PV HSC/
MPPs after 7 days in the cytokine-enriched serum-free
medium by 63–71% (Fig. 2E). In methylcellulose assays,
a 54–61% inhibition of total colony formation was
observed upon reconstitution/treatment with CXCL4/PF4
Fig. 2 (See legend on next page.)
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for FACS-sorted HSC/MPPs from PV patients (Fig. 2F).
Detailed analyses for colony subtypes as defined by
Manz et al.12 showed significant reductions in colony
growth from PV HSC/MPPs upon exposure to supple-
mental CXCL4/PF4 for CFU-GM (colony-forming
unit–granulocyte/macrophage) and BFU-E (burst-forming
unit–erythroid) (Fig. 2F). These results demonstrate that
CXCL4/PF4 is linked to HSC/MPP proliferation and dif-
ferentiation in PV, and reduced CXCL4/PF4 expression in
HSC/MPPs may contribute to the proliferative state of PV.
Discussion
This study identifies reduced CXCL4/PF4 protein
expression in HSC/MPPs of untreated PV patients com-
pared to controls. Treatment of patients with cytoreductive
hydroxyurea abrogated this effect. We demonstrated
transcriptional cessation of stem cell quiescence to be
associated with reduced CXCL4/PF4 expression in PV
HSC/MPPs, and supplementation with CXCL4/
PF4 strongly inhibited the in vitro colony-formation
capacity of HSC/MPPs from PV patients. These findings
extend previous reports in healthy hematopoietic stem cells
and non-PV JAK2-mutated erythroblast-like cells13.
CXCL4/PF4-/- mice were shown to exhibit increased
numbers and proliferation of HSCs and MPPs14, and high
CXCL4/PF4 levels were found to strongly inhibit hema-
topoiesis in non-PV mice14. The inhibitory role of CXCL4/
PF4 on HSPC proliferation in our PV patients supports a
key role of downregulated CXCL4/PF4 for the proliferative
phenotype of PV HSC/MPPs.
Mechanistically, we observed downregulation of TGFβ
signaling in untreated PV patients showing reduced
CXCL4/PF4 expression. CXCL4/PF4 was previously shown
to activate stem cell quiescence-inducing TGFβ10,11.
Upstream of CXCL4/PF4, we identified reduced activity of
the CXCL4/PF4-regulating transcription factors ELF18 and
USF25 in HSC/MPPs of untreated PV patients. Our data
thus support a model in which decreased ELF1 and USF2
activity in PV HSC/MPPs leads to reduced CXCL4/PF4
expression, which leads to decreased TGFβ signaling and
concomitant cessation of stem cell quiescence. Upon pro-
gression to post-PV MF, USF2 activity increased, explain-
ing elevated CXCL4/PF4 RNA levels in this patient group.
The PV disease stages and controls were better sepa-
rated by CXCL4/PF4 protein expression than by CXCL4/
PF4 RNA expression. Whereas transcriptomics reinforced
the proteomic results for CXCL4/PF4 in chronic phase
PV, discrepant RNA and protein levels were observed in
HSC/MPPs of post-PV MF patients. Our findings in
fibrotic patients are in line with recent observations of
upregulated CXCL4/PF4 RNA levels in co-cultured
HSPCs of a murine PMF model15. The congruent
CXCL4/PF4 protein and RNA expression in control,
chronic PV, and post-PV AML, but not in post-PV MF
suggests post-transcriptional regulation at the base of
discrepant RNA and protein levels in post-PV MF.
In summary, this study identified downregulation of
CXCL4/PF4 expression in HSC/MPPs with the cessation
of stem cell quiescence through downregulation of TGFβ
signaling as a potential new driver of the proliferative
state of PV.
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Fig. 2 CXCL4/PF4 protein is associated with transcriptional stem cell quiescence in untreated PV and inhibits the colony-formation
capacity of PV HSC/MPPs. A Activity analysis of transcription factors (TFs) regulating CXCL4/PF4 expression showed significantly downregulated
activity for the TF ELF1 and to a lesser degree for the TF USF2 in untreated PV patients compared to controls and HU-treated PV patients. Error bars
represent standard errors. *P < 0.05. B Gene set enrichment analysis showed strong and significant enrichment for genes downregulated in stem cell
quiescence in HSC/MPPs of untreated PV patients (PV.UT) compared to HSC/MPPs of controls, suggesting cessation of stem cell quiescence in PV
stem cells. C Treatment of patients with hydroxyurea (PV.HU.HSC/MPP versus PV.UT.HSC/MPP) reversed the loss of stem cell quiescence in the PV
HSC/MPP subpopulation. NES normalized enrichment score. D Heatmap of RNAs enriched in different patient/control groups for genes
downregulated in stem cell quiescence. The corresponding enrichment plots and heatmap for the protein level are shown in Supplementary Fig. 4A-
C. E Functional single-cell CXCL4/PF4 assay: colony growth of FACS-sorted HSC/MPPs from untreated chronic PV patients (PVchron.UT) singly
incubated in cytokine-enriched serum-free medium was assessed in presence or absence of CXCL4/PF4. Colony growth as depicted was evaluated in
864 wells after 7 days of incubation. In individual patients, significance was determined using Fisher’s exact test; significance overall was calculated
using two-tailed and paired Student’s t test (see Supplementary Methods). A strong growth inhibitory role of CXCL4/PF4 was observed.
F Methylcellulose colony assay: the growth of different myeloid colony subtypes from FACS-sorted HSC/MPPs of untreated chronic PV patients
(PVchron.UT) was evaluated in presence or absence of CXCL4/PF4. Reductions in colony growth due to CXCL4/PF4 protein were observed for all
colony subtypes with significant inhibitions seen in the CFU-GM and BFU-E colony subtypes as well as in composite granulocyte/macrophage (CFU-
GM and CFU-G and CFU-M) and erythroid (BFU-E and CFU-E) colonies. Relative numbers of colonies related to the total cell numbers plated are
plotted. Error bars represent standard deviations. *P < 0.05. CFU-GEMM (mixed colonies), CFU-GM colony-forming unit–granulocyte/macrophage,
CFU-G colony-forming unit–granulocyte, CFU-M colony-forming unit–macrophage, BFU-E burst-forming unit–erythroid, CFU-E colony-forming
unit–erythroid.
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